Falcon Point Capital LLC increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 338.6% during the second quarter, Holdings Channel reports. The institutional investor owned 1,100,474 shares of the medical research company’s stock after buying an additional 849,589 shares during the period. Falcon Point Capital LLC’s holdings in NeoGenomics were worth $9,860,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NEO. Gamco Investors INC. ET AL increased its position in shares of NeoGenomics by 14.9% in the first quarter. Gamco Investors INC. ET AL now owns 77,000 shares of the medical research company’s stock valued at $608,000 after buying an additional 10,000 shares during the last quarter. Icon Advisers Inc. Co. acquired a new position in shares of NeoGenomics during the first quarter valued at about $1,244,000. Renaissance Group LLC increased its position in shares of NeoGenomics by 1.1% in the first quarter. Renaissance Group LLC now owns 41,646 shares of the medical research company’s stock valued at $329,000 after buying an additional 470 shares during the last quarter. Suntrust Banks Inc. increased its position in shares of NeoGenomics by 0.6% in the first quarter. Suntrust Banks Inc. now owns 31,617 shares of the medical research company’s stock valued at $249,000 after buying an additional 184 shares during the last quarter. Finally, Monarch Partners Asset Management LLC acquired a new position in shares of NeoGenomics during the first quarter valued at about $295,000. Hedge funds and other institutional investors own 78.31% of the company’s stock.

Shares of NeoGenomics, Inc. (NASDAQ:NEO) opened at 9.49 on Friday. The stock’s market cap is $753.39 million. The stock has a 50 day moving average of $9.13 and a 200 day moving average of $8.22. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The business had revenue of $66.09 million for the quarter, compared to analysts’ expectations of $62.95 million. During the same quarter last year, the company earned $0.04 EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities analysts expect that NeoGenomics, Inc. will post $0.18 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/neogenomics-inc-neo-shares-bought-by-falcon-point-capital-llc/1478621.html.

Several research analysts have issued reports on the stock. ValuEngine raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. BTIG Research reissued a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research report on Sunday, May 28th. Finally, Cantor Fitzgerald set a $11.00 price objective on shares of NeoGenomics and gave the stock a “buy” rating in a research report on Saturday, May 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.40.

In related news, insider Steven A. Ross sold 70,833 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $7.76, for a total value of $549,664.08. Following the completion of the transaction, the insider now owns 4,500 shares in the company, valued at approximately $34,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alison L. Hannah bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of $9.19 per share, with a total value of $183,800.00. Following the transaction, the director now directly owns 38,782 shares in the company, valued at $356,406.58. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 84,890 shares of company stock worth $665,707. Corporate insiders own 12.20% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.